Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. (Nasdaq: NBIX) is a premier neuroscience-focused biopharmaceutical company based in San Diego. Established in 1992, the company is committed to developing and commercializing innovative pharmaceutical products that address unmet medical needs. Neurocrine Biosciences specializes in treatments for neurological, neuroendocrine, and neuropsychiatric disorders, impacting some of the largest pharmaceutical markets worldwide, including segments dealing with endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other related conditions.
The company’s extensive portfolio includes FDA-approved treatments such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, along with investigational candidates like elagolix, opicapone, and crinecerfont. Notable late-stage clinical programs are:
- Elagolix: A hormone-releasing antagonist for women's health, particularly in treating endometriosis and uterine fibroids in collaboration with AbbVie.
- Opicapone: A catechol-O-methyltransferase (COMT) inhibitor for Parkinson's disease patients.
- Ingrezza: For treating Tourette syndrome and other movement disorders.
Recently, Neurocrine announced the initiation of a Phase 1 clinical study for NBI-1076986, an investigational M4 subtype-selective muscarinic acetylcholine receptor antagonist aimed at treating movement disorders such as Parkinson's disease tremor and dystonia. This is part of their broader muscarinic receptor-focused portfolio, which includes a variety of small molecule M1, M1/M4, and M4 agonists acquired from Nxera Pharma.
Neurocrine's robust pipeline also includes the CAHtalyst™ studies, which focus on crinecerfont for congenital adrenal hyperplasia (CAH), demonstrating significant potential in reducing glucocorticoid doses while maintaining androgen control. Their recent presentations at the American Association of Clinical Endocrinology 2024 Annual Meeting and the European Congress of Endocrinology 2024 highlight their continuous advancements.
Financially, Neurocrine Biosciences maintains a strong position with a multi-billion-dollar product in INGREZZA, and a diverse pipeline of 17 clinical development programs. Notably, the company announced the retirement of CEO Kevin Gorman, Ph.D., with Kyle Gano, Ph.D., set to succeed him in October 2024, ensuring a seamless transition and continued focus on innovative treatments.
For more comprehensive insights and updates, visit Neurocrine Biosciences and follow them on LinkedIn, X (formerly Twitter), and Facebook.
Neurocrine Biosciences (NBIX) reported Q4 2020 revenues of $247.9 million, up from $244.1 million in Q4 2019. Full-year revenues reached $1.05 billion, a significant increase from $788.1 million in 2019. GAAP net income saw substantial growth, hitting $348 million or $3.58 per diluted share, largely due to a one-time tax benefit of $296 million. The company plans to invest $800-$850 million in combined R&D and SG&A for 2021, initiating eight mid-to-late-stage clinical studies. Notably, INGREZZA sales were $240 million for Q4 2020, reflecting a 1% increase compared to the previous year.
Neurocrine Biosciences (Nasdaq: NBIX) will report its fourth quarter and year-end 2020 financial results on February 4, 2021, after market close. A conference call and webcast will follow at 1:30 p.m. PT to discuss these results and provide a company update. Interested participants can join the call using the provided access numbers or through the company’s website. Neurocrine focuses on developing treatments for neurological and psychiatric disorders, boasting a portfolio that includes FDA-approved therapies.
Neurocrine Biosciences (Nasdaq: NBIX) reported preliminary net product sales for INGREZZA of approximately $240 million in Q4 2020 and $993 million for the full year. The company noted a 32% growth in total INGREZZA prescriptions in 2020, reaching 175,700 versus 132,700 in 2019. Key 2021 milestones include Phase III data for valbenazine in Huntington's disease expected in Q4 2021 and the initiation of several clinical studies. CEO Kevin Gorman highlighted the commitment to improving treatment accessibility for tardive dyskinesia patients.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 2:00 p.m. Eastern Time. CEO Kevin Gorman will lead the presentation, which will be available via live webcast on the company's website. A replay will be accessible one hour post-event and archived for a month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease. For more information, visit neurocrine.com.
Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at two investor conferences. Matt Abernethy, CFO, and Eiry Roberts, CMO, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 23, 2020, at 10:00 a.m. ET. Additionally, CEO Kevin Gorman and CFO Abernethy will present at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 1:50 p.m. ET. Live webcasts will be available on their website, with replays accessible for one month.
Neurocrine Biosciences (Nasdaq: NBIX) has initiated a repurchase of approximately $83 million of its 2.25% Convertible Senior Notes due 2024. The aggregate repurchase price is estimated at $110 million based on the closing stock price of $86.91 on November 18, 2020. The transaction is expected to close on December 2, 2020. This strategic buyback aims to potentially enhance shareholder value, but may also impact the market price of the company's common stock.
Neurocrine Biosciences (NBIX) reported Q3 2020 revenues of $258.5 million, a 16.4% increase from $222.1 million in Q3 2019, driven by a 28% rise in INGREZZA sales to $254 million. However, the company faced a GAAP net loss of $57.6 million compared to a profit of $53.8 million in the previous year, largely due to increased R&D expenses. The guidance for combined GAAP R&D and SG&A expenses was raised to between $880 million and $900 million. Despite the challenges, the company expressed confidence in its growth prospects, particularly for INGREZZA and the newly launched ONGENTYS.
Neurocrine Biosciences (Nasdaq: NBIX) announced upcoming presentations at investor conferences. Kevin Gorman, CEO, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 11:20 a.m. ET. On November 17, 2020, at 9:40 a.m. ET, Gorman and CFO Matt Abernethy will present at the Jefferies Virtual London Healthcare Conference. Both presentations will be available via webcast on Neurocrine's website, with replays accessible for one month.
Neurocrine focuses on developing treatments for neurological and endocrine disorders.
Neurocrine Biosciences (Nasdaq: NBIX) will report its third-quarter financial results after market close on November 9, 2020. A conference call will follow at 1:30 p.m. PT, 4:30 p.m. ET, to discuss the results and provide updates. Participants can access the call at 877-830-2596 (US) or 785-424-1744 (International) with conference ID: NBIX. The event will be available for replay on the company's website for approximately one month. Neurocrine specializes in developing treatments for neurological and psychiatric disorders.
On September 28, 2020, Neurocrine Biosciences (Nasdaq: NBIX) announced new data on ONGENTYS® (opicapone) capsules, the first once-daily COMT inhibitor approved by the FDA for Parkinson's disease patients experiencing 'off' episodes. Phase III analyses reveal ONGENTYS significantly reduces overnight 'off' time and motor fluctuations compared to entacapone. This data will be presented at the American Neurological Association 2020 Virtual Meeting. ONGENTYS also shows promise in lowering daily levodopa requirements, enhancing 'on' time without troublesome dyskinesia.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
What does Neurocrine Biosciences Inc. specialize in?
What are some key products of Neurocrine Biosciences?
What recent advancements has Neurocrine Biosciences made?
Who announced their retirement from Neurocrine Biosciences in 2024?
What is the focus of Neurocrine Biosciences' muscarinic receptor portfolio?
Where is Neurocrine Biosciences headquartered?
How can I learn more about Neurocrine Biosciences?
What impact has INGREZZA had on Neurocrine Biosciences?
What are the CAHtalyst™ studies?
What was the focus of Neurocrine Biosciences' recent presentations at ENDO 2024?
